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ABSTRACT  
At present no scientific rationale exists for selecting a particular enabling strategy to 
formulate a poorly water-soluble drug, although this is crucial as it will influence the in vivo 
performance of the resulting formulation. This study provides an insight into this complicated 
decision making process for a poorly soluble human immunodeficiency virus (HIV) protease 
inhibitor based upon in vivo test results. A formulation strategy based on the molecular 
dispersion of this active pharmaceutical ingredient (API) into a biphasic matrix consisting of 
water-insoluble poly(lactic-co-glycolic acid) (PLGA) and water-soluble polyvinylpyrrolidone 
(PVP) was evaluated. The long-term in vivo performance of this strategy was compared to 
that of other solubility enhancing approaches by evaluating the exposure in male Beagle dogs. 
Solid dispersions, based on a PLGA/PVP matrix, were compared to solid dispersions in a pure 
water-insoluble PLGA matrix. Additionally these solid dispersion strategies were compared to 
the strategy of particle size reduction by means of an API microsuspension. The in vivo 
performance of the various formulations over a period of 28 days after intramuscular injection 
was evaluated by the observed initial burst release, plasma concentration-time profiles, time at 
which maximum plasma levels were reached (tmax,obs) and the estimated bioavailability. 
Compared to the other formulation strategies assessed, it was concluded that the addition of 
PVP in a PLGA matrix resulted in vivo in a more sustained release as well as a higher amount 
of drug released from the polymeric matrix. This was explained based on the structure of 
these binary PLGA/PVP matrices where the pore network originating from rapidly dissolving 
PVP plays a crucial role. Moreover, the results suggest that the release of this type of 
formulations could be delayed by increasing the amount of PLGA in the formulation. 
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INTRODUCTION 
Contemporary drug pipelines contain an increasing number of poorly water-soluble 
candidates. To overcome this problem, solubility enhancing technologies often focus on 
impacting aspects of the modified Noyes-Whitney relationship by increasing dissolution rate 
or drug solubility. Examples of these approaches for solubility enhancement are the solid 
dispersion of a poorly soluble active pharmaceutical ingredient (API) in an inert matrix, 
particle size reduction, the use of co-crystals, inclusion complexation with cyclodextrins and 
lipid based systems [1]. At present no scientific rationale exists for selecting a particular 
enabling strategy, although this is crucial as it will influence the in vivo performance of the 
resulting formulation. The present study provides an insight into this complicated decision 
making process for a poorly soluble human immunodeficiency virus (HIV) protease inhibitor 
(PI) based upon in vivo test results. 
 
This poorly soluble model compound needs formulation into an effective long-acting 
medicine for HIV pre-exposure prophylaxis therapy. Long-acting injectables have been 
introduced to prevent the transmission of HIV via pre-exposure prophylaxis and could for 
example be effective in preventing mother-to-child transmission, transmission within 
serodiscordant couples as well as protecting intravenous drug users [2]. Long-acting 
formulations are desirable as dosing frequency will be significantly reduced, favouring 
therapy compliancy. Additionally, they allow sustained release of appropriate amounts of 
drug resulting in constant low drug plasma concentrations which is sought-after for this HIV 
pre-exposure prophylaxis approach. 
 
In view of this, we previously reported on the development of spray-dried polymeric 
microspheres for intramuscular injection for the long-term pre-exposure prophylaxis of 
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infection with HIV [3,4]. Our formulation strategy was based on the solid dispersion of a 
poorly soluble API in a polymeric matrix consisting of water-soluble polyvinylpyrrolidone 
(PVP) and water-insoluble poly(lactic-co-glycolic acid) (PLGA). This combination of 
materials aimed to secure both solubility enhancement by molecular dispersion of the drug (in 
PVP) and long-term release (by PLGA) (strategy 1). 
 
In the present study the in vivo behaviour of the formulation strategy of a solid dispersion in a 
binary polymeric matrix combining a water-insoluble polymer (PLGA) with a water-soluble 
polymer (PVP) (strategy 1) was evaluated in male Beagle dogs. The in vivo performance of 
this formulation strategy was compared to the in vivo performance of two other strategies. The 
second strategy was based on formulating the poorly soluble API as a solid dispersion in a 
polymeric matrix made up of pure PLGA. PLGA is already well established as a formulation 
matrix for long-term release as exemplified by commercial products like Trelstar
®
 Depot 
(Debio RP) [5] and Risperdal
®
Consta
®
 (Janssen Pharmaceutica) [6]. Hence, the current 
formulations differed at the level of the polymeric matrix and can be divided in two groups, 
namely formulations based upon a PLGA/PVP matrix (strategy 1) vs formulations made up of 
a pure PLGA matrix (strategy 2). Consequently the potential benefit of the inclusion of PVP 
was assessed.  
Additionally, these solid dispersion strategies were compared to the strategy of particle size 
reduction by means of an API microsuspension (strategy 3). Particle size reduction is a well 
described strategy to increase dissolution rate of poorly soluble compounds. This is 
exemplified by various publications on micro- and nanoparticles aiming to improve the 
dissolution performance of a poorly soluble compound [1,7,8]. This strategy has already 
resulted in the production of successfully marketed formulations such as Invega
®
 Sustenna
®
 
[9] (Janssen Pharmaceutica) and Triglide
®
 (Sciele Pharma Inc) [10]. 
5 
 
Previously six intramuscularly (IM) injectable sustained release formulations for HIV 
prophylaxis with a poorly soluble PI were developed and physicochemically characterized 
[11]. These six formulations (F1-F6, Table 1) represent the three different solubility 
enhancing strategies selected. F1-F3 exemplify the first strategy, being solid dispersions of 
the poorly soluble API in a PLGA/PVP-based matrix. A comparison of F1 and F2 
demonstrates the influence of an increase in the amount of PLGA (from 25 to 45 wt%). 
Additionally, F3 was developed to assess the influence of the molecular weight of PVP used.  
F4 and F5 represent the second formulation strategy which is the solid dispersion of the PI in 
a pure PLGA matrix. Here, the influence of the manufacturing method was assessed by 
comparing a spray-dried formulation (F4) to a formulation prepared by the emulsion method 
(F5). F6 is representative of the third formulation strategy selected, being particle size 
reduction. Summarized the six formulations differed in composition and manufacturing 
method and consequently in structural and physicochemical characteristics (Fig. 1) [11]. In 
the current study the in vivo performance of these six formulations, representing three 
formulation strategies, is evaluated in male Beagle dogs. 
 
 
EXPERIMENTAL METHODS  
MATERIALS 
Poly(lactic-co-glycolic acid) (PLGA) (lactide:glycolide molar ratio of 75:25, inherent 
viscosity of 0.2 dl/g) was purchased from PURAC Biomaterials (Gorinchem, The 
Netherlands). Polyvinylpyrrolidone K30 (PVP K30) (MW 44-54 kDa) and 
polyvinylpyrrolidone K12 PF (PVP K12) (MW 2-3 kDa) were kindly donated by BASF 
(Ludwigshafen, Germany). The API was a poorly soluble HIV protease inhibitor (PI) 
provided by Janssen Pharmaceutica (Beerse, Belgium). The structural formula is shown in 
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Figure 2.  Polyvinyl alcohol (PVA) (80% hydrolyzed, MW 9-10 kDa) was obtained from 
Sigma-Aldrich (Diegem, Belgium). Tocopheryl polyethylene glycol 1000 succinate (TPGS) 
was supplied by Eastman Chemical Company (Anglesy, UK). Dichloromethane (DCM) was 
provided by Fisher Scientific (Leicestershire, United Kingdom).  
 
 
METHODS 
Table 1 provides an overview of the composition and manufacturing method of various 
formulations tested. From here on the formulations will be indicated by their code F1-F6 as 
shown in Table 1. 
 
Table 1. Overview of formulation composition and manufacturing method.  
 
 
Formulation manufacturing 
Spray drying 
F1-F4 were spray dried with a Micro Spray lab scale spray dryer (ProCepT, Zelzate, Belgium) 
starting from a 5% feed solution in dichloromethane (DCM). The inlet temperature was set to 
115°C and the feed rate was 6 mL/min. The co-current drying air had a flow rate of 0.2 
m³/min and the atomizing air was supplied with a pressure of 1.25 bar.  
 
Oil-in-water emulsion method 
Formulation Composition (w%)  Manufacturing method 
Formulation 1 (F1) API/PLGA/PVP K30 30/25/45 Spray drying  
Formulation 2 (F2) API/PLGA/PVP K30 30/45/25 Spray drying 
Formulation 3 (F3) API/PLGA/PVP K12 30/45/25 Spray drying 
Formulation 4 (F4) API/PLGA 30/70 Spray drying 
Formulation 5 (F5) API/PLGA 30/70 Emulsion method 
Formulation 6 (F6) API microsuspension  Media milling 
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Microspheres of API/PLGA were produced using an oil-in-water (o/w) emulsion method 
(F5). 900.0 mg of API was dissolved in 30.0 mL DCM together with 2100.0 mg PLGA.  This 
solution was emulsified in 150.0 mL of a 1.25% PVA solution for 5 minutes using an Ultra 
Turrax
®
 homogenizer (IKA, Staufen, Germany) at 20,000 rpm to form the o/w emulsion. 
During homogenization the sample was placed in an ice bath to minimize heating. After 
addition of 150.0 mL of distilled water, the suspension was stirred overnight with a magnetic 
stirrer to allow the organic solvent to evaporate as the microparticles hardened. The resulting 
microparticles were harvested and washed three times with deionized water. As a last step the 
microparticles were freeze dried and consequently stored in a desiccator at room temperature. 
 
Media milling of the microsuspension  
The API microsuspension (F6) was prepared using a roller mill (Peira, Turnhout, Belgium) 
and glass vials of the appropriate size filled with zirconium oxide grinding beads with a 
diameter of 1.0 mm (Tosoh Corporation, Tokyo, Japan). All samples were ground for 24 h. 
Subsequently these beads were replaced by beads of ø 0.5 mm. After 48 h ø 0.3 mm beads 
were used for the next 16 days. Suspensions consisted of 10% of drug in phosphate buffer of 
pH containing 3.75% of TPGS.   
 
In vivo performance 
Intravenous drug administration 
An intravenous (IV) infusion study was performed to determine the area under the curve 
(AUC) of the plasma concentration-time profile for IV dosing as well as the half-life (t1/2) of 
the API. For this study three male Beagle dogs were fasted approximately 16 h before dosing 
and food was returned approximately 4 h post dosing. The infused formulation was prepared 
in a mixture of polyethylene glycol (PEG) and water (PEG/water 70/30 v%) at a final 
8 
 
analyzed concentration of 0.923 mg/mL. The test subjects were infused in a cephalic vein at a 
dose of 1 mL/kg for 1 h at an infusion rate of 1 mL/h/kg. Hence the obtained final dose was 
0.923 mg/kg. Blood samples were collected from a saphenous vein 15 min, 30 min and 1 h 
after the start of the infusion and 2, 7 and 20 min and 1, 2, 3, 4, 5 and 6 h after the end of the 
infusion. Immediately after collection, the blood samples were placed on melting ice till 
centrifugation. 
Within 1 h after blood collection, blood samples were centrifuged at 1900 g for 10 minutes. 
The plasma was separated and stored at -20
о
C till bioanalysis. 
 
Intramuscular drug administration 
The six formulations (F1-F6) were intramuscularly injected, each in four male Beagle dogs. 
Prior to IM drug administration the test subjects were fasted approximately 16 h before dosing 
and food was returned approximately 4 h post dosing. Before administration, the 
microspheres of F1-F5 were suspended in 3.75% TPGS containing phosphate buffer of pH 7. 
For all formulations the administered drug dose was 23 mg/kg. Blood samples were collected 
0.5, 1, 2, 4, 6, 24, 55, 79, 223, 343, 511 and 679 h post dosing from a saphenous vein. 
Immediately after collection, the blood samples were placed on melting ice till centrifugation. 
Within 1 h after blood collection, blood samples were centrifuged at 1900 g for 10 minutes. 
The plasma was separated and stored at -20
о
C till bioanalysis. 
 
Bioanalysis  
Plasma levels of the API were determined using a qualified research liquid chromatography - 
mass spectrometry/mass spectrometry (LC-MS/MS) method. After protein precipitation (with 
acetonitrile) plasma samples were quantified on a reversed phase ultra-high performance 
liquid chromatography (UHPLC) column (Acquity BEH C18 1.7 µm, 2.1 x 50 mm; Waters, 
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Milford, USA).  Mobile phases consisted of 0.1% formic acid (solvent A) and acetonitrile 
(solvent B). Starting conditions were 60% solvent A and 40% solvent B followed by a linear 
gradient to 2% solvent A and 98% solvent B over 1.0 min followed by an isocratic hold at a 
flow rate of 0.6 mL/min.  
LC-MS/MS analysis was carried out on an API-4000 MS/MS (Applied Biosystems, Toronto, 
Canada), which was coupled to an UHPLC-system (Nexera; Shimadzu, Kyoto, Japan). The 
MS/MS, operated in the positive ion mode using the TurboIonSpray-interface (electrospray 
ionization), was optimized for the quantification of the compound. Multiple reaction 
monitoring (MRM) transition was as follows: 575. > 419.2. Samples were quantified against 
calibration curves prepared to cover the concentration range of the study samples. The curves 
were prepared in the same matrix as the study samples. For each analytical batch, independent 
quality control (QC) samples, prepared in the same matrix as the samples, were analyzed 
together with the study samples and calibration curve. The limit of quantification in canine 
plasma was at least 2 ng/mL. The accuracy (intra batch accuracy from independent QC 
samples) was between 85% and 115% of the nominal value over the entire range for plasma 
samples. 
 
Pharmacokinetic data analysis 
Based on the plasma concentration-time profiles obtained by the IV infusion study the half-
life (t1/2) of the API was determined via equation 1. 
t1/2   = 0.693 / (terminal slope * 2.303)     (1) 
The terminal slope was obtained by linear regression of the logarithm of the plasma 
concentrations 2, 3, 4, 5 and 6 h after the end of the infusion. 
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The AUC for both the intravenously and the intramuscularly dosed API (AUCIV and AUCIM 
respectively) was calculated based on the plasma concentration-time profiles using the linear-
up log-down trapezoidal method. After the last time point (h(final)) the plasma concentration-
time profile was extrapolated to infinity in order to determine AUC0-∞. Equation 2 was used 
to estimate AUC h(final) -∞. 
AUC h(final)-∞ = plasma concentration h(final) / terminal slope  (2) 
The terminal slope was obtained by linear regression of the plasma concentrations for the 
three last time points at which detectable API plasma levels observed. 
 
For each intramuscularly administered formulation, the measured plasma exposure was used 
to calculate the bioavailability (F) (0-∞) by equation 3. 
F = 100 * (doseIV * AUCIM, 0-∞)/(doseIM * AUCIV, 0-∞)    (3) 
The intravenously administered dose (doseIV) of 0.92 mg/kg and an intramuscularly 
administered dose (doseIV) of 23 mg/kg.  
 
The initial burst release of the six formulations was determined based on the observed plasma 
concentration till 4 h post administration. The percentage of drug released within this 
timeframe was calculated by equation 4. 
Initial burst = 100 * (AUCIM,0-4h)/( AUCIM, 0-∞)    (4) 
In this equation AUCIM,0-4h and AUCIM, 0-∞ represent the calculated AUCs based upon the 
plasma concentration-time profile till 4h post administration and extrapolated to infinity 
respectively.  
 
Statistical analysis 
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Statistical differences between the observed time after administration when maximum plasma 
concentrations were reached (tmax,obs) for each of the formulations were evaluated via one-way 
ANOVA as well as the initial burst release (4h post administration) and bioavailability. A 
Bonferroni post-hoc test was performed at an α level of 0.05. (GraphPad Prism 5 for 
Windows; GraphPad Software Inc., San Diego, USA). 
 
 
Mimicking suspension and injection 
To investigate the effect of the suspension of the powders of F1-F5 in an aqueous medium 
and subsequent IM injection this process was mimicked in vitro. F1 was selected as a 
representative for the PLGA/PVP-based formulations (F1-F3) whereas F4 was chosen as an 
example for the PLGA-based formulations (F4-F5). Powder of both samples was suspended 
in the same suspension medium and concentration as used for IM injection in the canine test 
subjects (3.75% TPGS containing phosphate buffer of pH 7, 100 mg API/mL). Injection was 
mimicked by injecting the suspended powders via a 20 G needle into a glass petri dish. The 
resulting sample was dried in a vacuum oven C for one week at 25° and subsequently stored 
in a desiccator at room temperature. 
 
Scanning electron microscopy 
Scanning electron microscopy (SEM) was used to gain insight into the morphology of the 
samples obtained by mimicking suspension and injection for F1 and F4. Samples prepared by 
fixing an amount of powder on an aluminum stub using double-sided carbon tape. The 
samples were coated with a gold-palladium mixture by sputtering for 45 s at 20 mA. Field 
emission gun scanning electron micrographs (FEG-SEM) were taken by using a Philips XL30 
12 
 
ESEM-FEG instrument (Philips, Eindhoven, The Netherlands) at an acceleration voltage of 
10 kV.  
 
RESULTS  
Intravenous infusion study 
The IV infusion study was performed to determine the pharmacokinetic parameter t1/2 of the 
API which was calculated to be 1.1 (± 0.4) h respectively. Additionally, the IV infusion study 
resulted in a mean (±SD) AUC for the intravenously dosed API (AUCIV) of 426 (± 135) 
h*ng/mL.  
 
Plasma concentration-time profiles 
Figure 3 shows the plasma concentration-time profiles up to 28 days after IM injection of the 
six formulations with Figure 4 depicting these profiles up to 5 h after administration. For all 
formulations except for F4 the mean plasma concentrations presented are based on the 
observed plasma concentrations of four animal subjects. For F4 the mean plasma 
concentrations presented are based on the observed plasma concentrations of three animal 
subjects as the plasma concentrations of the fourth subject 511 h and 679 h post dosing were 
considered as outliers (as verified by the statistical criterion of Dean and Dixon). Figure 1 of 
the supplementary information shows the individual plasma concentration-time profiles for 
the four test subjects (dog 1-4) of F4. These profiles suggest an initial underperforming of F4 
in dog 4, illustrated by lower plasma concentrations compared to dogs 1, 2 and 3. However, 
511 h post administration a change in exposure is observed which might be attributed to dose 
dumping and reflects on the plasma concentration observed 679 h post dosing. Because F4 
behaves different in dog 4, the results for this test subject were not used to calculate the 
average plasma concentrations. 
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Between 0.5 and 5 h post administration the microsuspension F6 and the binary, PLGA-based 
formulations F4 and F5 demonstrate more rapidly decreasing plasma concentration-time 
profiles (Fig. 4) which is in contrast to the more constant profiles of the PLGA/PVP based 
matrices (F1-F3). From roughly two days (55 h) after injection until the end of the study (28 
days) the PLGA/PVP-based matrices (F1-F3) show similar plasma concentration-time profiles 
with F2 having the highest average plasma concentrations followed by F1 and F3 (Fig. 3). 
Sample F2 shows the highest average plasma concentration from three days after 
administration (79 h) until the end of the study.  
Table 2 represents the observed time after administration when maximum plasma 
concentrations were reached (tmax,obs) for each of the formulations. The binary formulations F4 
and F5 and the microsuspension F6 have a mean tmax,obs of 0.5 h, whereas for the ternary 
formulations F1, F2 and F3 the average tmax,obs is  2.0, 3.0 and 1.5 h respectively. However, 
for these ternary formulations the tmax,obs for the individual test subjects varied between 0.5 h 
and 4 h, in contrast to F4-F6 where for all test subjects a tmax,obs of 0.5 h was observed. Due to 
the large standard deviations differences between tmax,obs were not statistically significant. 
 
Bioavailability 
For each formulation, the observed plasma concentrations were used to calculate the 
bioavailability by equation 3. The results are shown in Figure 5 where the bioavailability 
values, based upon the observed plasma concentrations until 28 days after administration 
(calculated based on AUC0-∞), are depicted. For all formulations the bioavailability is 
considered as a measure for the amount of drug released, assuming linear elimination kinetics. 
After IV administration, very rapid elimination of the drug was observed, as reflected by the 
t1/2 value, obtained by the IV infusion study, of 1.0 h ± 0.4 h. This suggests that declining 
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plasma concentrations observed during terminal “elimination phases” for IM administered 
formulations are very likely limited by the (much slower) absorption rates (flip-flop kinetics).  
 
The amount of drug released from the various formulations was evaluated by comparing the 
bioavailability (Fig. 5). F2 showed the highest average bioavailability and therefore drug 
release, followed by the microsuspension F6 with a mean bioavailability for F2 of 101% and 
of 81% for F6 (Fig. 5). Subsequently the other two ternary PLGA/PVP-based formulations, 
F1 and F3, released API resulting in an average bioavailability of 72% and 59% respectively. 
The bioavailability for both F2 and F6 was significantly higher compared to that for the 
binary formulations, F4 and F5. These PLGA-based formulations had the lowest total drug 
release with average bioavailability values of 35% and 34% (Fig. 5).  
 
Burst release 
Burst release was identified based on the plasma concentrations obtained within 4 h after 
administration. This time point was selected as by then all plasma concentration-time profiles 
had reached their maximum plasma concentration. F4 and F6 display a significantly higher 
initial burst release compared to the other formulations which is illustrated in Figure 4 by 
higher plasma concentrations already 30 min after IM injection. For each formulation, the 
observed initial burst release was calculated by equation 4 and the results are shown in Figure 
6. The obtained values represent the percentage of drug released, during the first four hours 
post injection, of the total amount of drug released by the formulation. The results are shown 
in Figure 6 where the percentage of drug released values after 4 h (as a measure for burst 
release) are depicted. The average initial burst release of F6 represents 15% of the total 
amount of drug released, whilst for F4 this is 13%. The average burst release for F1, F2, F3 
and F5 is 4% of the total amount of drug administered. Hence, the burst release of F6 is on 
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average almost four times higher compared to the burst release of F1, F2, F3 and F5. The 
burst release of F4 is on average three times higher compared to F1, F2, F3 and F5.  
 
Mimicking suspension and injection 
To investigate the effect of the suspension of the powders of F1-F5 in an aqueous medium 
and subsequent IM injection this process was mimicked in vitro. F1 was selected as a 
representative for the PLGA/PVP-based formulations (F1-F3) whereas F4 was chosen as an 
example for the PLGA-based formulations (F4-F5). SEM images illustrate that before 
injection and exposure to an aqueous environment both formulations consist of microspheres 
with a comparable, spherical morphology and a smooth, intact surface (Fig. 8A and 8B). The 
friction caused by forcing the suspension through the needle did not result in rupture of the 
shell structured microspheres. However, after exposure to an aqueous environment (the 
suspension medium) the microspheres of both model formulations show a distinct 
morphology. The particles of F4 are still spherical with an intact and smooth surface whereas 
the particles of F1have a more irregular shape (Fig. 8C and 8D).  
 
 
DISCUSSION  
Previously the six formulations F1-F6, representing the three different formulation strategies,  
have been physicochemically characterized [11]. Physicochemical characterization of these 
model formulations showed that all ternary formulations (F1-F3) existed as a PLGA-rich 
surface layer containing small amounts of PVP and an underlying PVP-rich phase containing 
small amounts of PLGA. The API was molecularly dispersed in the polymeric matrix. 
Additionally for F2, a separate amorphous drug phase was detected. The binary formulations, 
F4 and F5, contained a molecular dispersion of the drug as well. Furthermore F5 contained a 
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crystalline drug fraction and had a higher drug surface coverage. F5 had a larger particle size, 
with a d50 value of 5.62 µm, compared to the d50 value of the other formulations which was 
averagely 2.99 µm. Moreover, the higher surface area of F5 compared to F1-F4 indicates that 
particles of F5 are more porous. The different manufacturing method of F5 compared to F1-
F4 (emulsion method versus spray drying) is held responsible for these observed differences 
in particle characteristics. The polymeric formulations, F1-F5, are schematically represented 
in Figure 1. The microsuspension F6 existed of both crystalline and amorphous API. 
Summarized the six formulations differed in composition as well as structural and 
physicochemical characteristics. In the current study the in vivo performance of these 
formulations was evaluated in male Beagle dogs. 
 
Solid dispersions in a water-insoluble PLGA matrix (F4-F5) 
The two binary, PLGA-based formulations differed in that the spray-dried formulation (F4) 
showed a significant initial burst release in vivo, in contrast to the formulation prepared by the 
emulsion method (F5) (Fig. 4 and 6). This burst release was not only significantly higher 
compared to the burst release observed for F5, but also compared to the burst observed for the 
ternary formulations F1-F3. Subsequently this burst was followed by a fast decline in plasma 
concentration (Fig. 4). This initial burst for F4 represented 13% of the total amount of drug 
released, in contrast to F5, for which the burst release accounted for 5% of the total amount of 
drug released. This implies that for F5 the drug is more gradually released compared to F4 
and therefore F5 is more suitable for sustained release.  
The difference in manufacturing methods between both formulations did not have a 
significant influence upon their observed mean bioavailability (35% and 34%) and hence the 
total amount of drug released (Fig. 5). Both binary formulations showed a lower average 
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bioavailability compared to the ternary formulations (Fig. 5) indicating the advantage of 
inclusion of PVP in terms of the extent of drug released from these formulations.  
The early tmax,obs (0.5 h, Table 2) combined with the fast decrease in plasma concentration-
time profiles for formulations F4 and F5 suggest that they are less suitable for long-term 
release compared to the ternary formulations, for which a more constant and prolonged 
release is observed (Fig. 4). These observations suggest the benefit of inclusion of PVP in the 
polymeric matrix to obtain a more sustained release. 
Noteworthy was the fact that in one of the four test subjects of F4 three weeks after 
administration a late burst release was observed. This late burst resulted in a total amount of 
85% of drug released compared to an average value of 35% for the three other test subjects. 
This high drug release might be attributed to sudden erosion of the PLGA matrix and 
consequently disintegration of the microspheres. This divergence in velocity of the erosion of 
the PLGA matrix and the consequent differences in the observed release profile between the 
different test subjects is a restriction of this formulation strategy. 
 
 
 
 
 
Table 2. Pharmacokinetic parameter tmax (mean ± SD, n=4). 
 
Solid dispersions in a biphasic matrix consisting of water-insoluble PLGA and a water-
soluble PVP (F1-F3) 
Figure 4 demonstrates the more constant and prolonged plasma concentration-time profiles 
(0.5-5 h after injection) of the PLGA/PVP-based matrices compared to the other formulations 
which suggests that these PLGA/PVP matrices are more suitable for sustained release. The 
Formulation tmax (h) 
F1  2.0 ± 1.2 
F2 3.0 ± 1.0 
F3  1.5 ± 1.5 
F4 0.5 ± 0 
F5  0.5 ± 0 
F6  0.5 ± 0 
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higher mean bioavailability of these ternary formulations compared to the binary formulations 
indicates a higher drug release (Fig. 5). F2 showed the highest bioavailability (101%) 
suggesting that essentially all drug present in this formulation is released.  
 
Overall, when the binary PLGA-based formulations were compared to the ternary 
PLGA/PVP-based formulations it can be concluded that the addition of PVP was beneficial 
for both the amount of drug released and sustained drug release. This can be explained by the 
structure of the PLGA/PVP-based matrices which are known to consist of a PLGA-rich 
surface layer containing small amounts of PVP and an underlying PVP-rich phase containing 
small amounts of PLGA [3,4]. Consequently the release mechanism is dominated by fast 
dissolution of the small domains of PVP present in the PLGA layer due to the high solubility 
of PVP. The resulting pores in the PLGA surface layer allow ingression of aqueous fluids into 
the particles, followed by fast dissolution of the molecularly dispersed API and diffusion out 
of the microspheres. Hence, the presence of PVP in the PLGA matrix results in a higher 
extent of drug release as the resulting pores allow water ingression deeper into the particle 
compared to into a bulk eroding PLGA matrix. Consequently an increased surface area is 
exposed to the release medium with an increase in drug dissolution and drug release as a 
result (Fig. 7A). Additionally the hydrophilic nature of PVP will favour water ingression into 
the pore network. Moreover, PVP itself is known to increase the solubility of this API [12]. 
Analogously PVP contributes to the long-term release of these formulations as the pore 
network originating from dissolved PVP expands deeper into the particles with longer 
exposure to the aqueous environment. This results in an increasing access to the API 
dispersed in the polymeric matrix with depth from the surface which acts as a reservoir (Fig. 
7B). Altogether, the pore network originating from dissolved PVP controls the observed drug 
release. A schematic representation is given in Figure 7 where the structural evolution of a 
19 
 
PLGA/PVP-based matrix when exposed to a release environment is compared to that of a 
PLGA-based matrix. The difference in structural evolution of a PLGA/PVP-based matrix 
compared to a PLGA-based matrix when exposed to an aqueous milieu is demonstrated by the 
SEM images in Figure 8. F1 was selected as a representative for the PLGA/PVP-based 
formulations whereas F4 was chosen as an example for the PLGA-based formulations. It is 
clear that after exposure to an aqueous environment the microspheres of both model 
formulations show a distinct morphology. The particles of F4 are still spherical with an intact 
and smooth surface whereas the particles of F1 have a more irregular shape due to the 
dissolved PVP. This induces an increased access and ingression of water into these particles 
via the resulting pores. This enables the exposure of an increased surface area with 
consequently an increase in drug dissolution and drug release. 
 
From the three ternary formulations F3 appears the least suitable for sustained release which 
is suggested by its lower averge tmax,obs compared to F1 and F2 (Table 2). Additionally the fact 
that no detectable plasma concentrations are observed after three weeks (511 h) indicates that 
there was no longer significant drug release (Fig. 3). From the three PLGA/PVP-based 
formulations F3 has the lowest bioavailability (Fig. 5). These observations indicate an 
influence of the molecular weight of PVP used as this formulation only differs from F2 by the 
molecular weight of PVP (PVP K12 vs PVP K30). Hence the use of PVP with a lower 
molecular weight results in less prolonged drug release as well as a lower amount of drug 
released. This would allow tailoring the desired release profile by changing the molecular 
weight of the PVP used.  
Comparing the plasma concentration-time profiles of F1 and F2 indicate that F2 results in 
higher average plasma concentrations by the end of the study (Fig. 3). Additionally its higher 
mean tmax,obs suggests that an increase in the amount of PLGA from 25 to 45 wt% results in a 
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more sustained release (Table 2). This is not surprising as previous research demonstrated that 
the thickness of the PLGA surface layer increased with a raise in the amount of PLGA in the 
microspheres [3]. As PLGA is water insoluble it is expected that the thickness of this PLGA 
surface layer has an influence upon drug release kinetics where the thicker the PLGA layer, 
the more prolonged the observed release. The prolonging influence of PLGA on the release 
could be increased by increasing the amount of PLGA present in the formulation. Comparing 
the bioavailability of F1 and F2 suggests that the amount of PLGA present in the formulations 
also influences the amount of drug released. This might be attributed to the fact that changing 
the PLGA/PVP ratio influences the miscibility of the system. This will result in a difference 
in the PVP pore network and might consequently influence the release. All ternary 
formulations showed a comparable initial burst (Fig. 6) 
 
Suspension of the powders of the polymeric formulations F1-F5 with a concentration of 100 
mg/mL resulted in a viscous suspension. This impeded facile injection of these formulations. 
Lowering the concentration of the injected formulation could be one approach to facilitate 
injection of these formulations. 
 
Particle size reduction (F6) 
Particle size reduction is a well-known strategy to increase the dissolution rate of a drug via 
an increase in surface area [1,7,8]. However, for poorly soluble APIs particle size reduction 
will still result in a relatively low dissolution rate and hence sustained release [2,13,14]. 
Consequently, for this type of API, particle size reduction is often used as a strategy to 
develop a sustained release formulation which was the approach investigated here by means 
of F6. 
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The microsuspension showed an initial high burst release of the API and reached maximum 
plasma concentrations 0.5 h after administration (Fig. 4). Four hours post administration 15% 
of the total amount drug released was already released (Fig. 6). The observed burst release 
was followed by a fast decline in plasma concentrations between 0.5 and 6 h after 
administration (Fig. 4). F6 was also the only formulation for which no detectable plasma 
concentrations could be observed from two weeks (343 h) after injection onwards (Fig. 3). 
These observations illustrate that of all formulations tested this microsuspension is the least 
suitable for sustained release applications for this API. The faster drug release can be 
attributed to the reduction in particle size, used as dissolution rate enhancing strategy for this 
formulation.  
Furthermore, the mean bioavailability of 81% for this formulation indicates that although 
particle size reduction increased dissolution rate, less drug was released or reached the 
systemic circulation compared to F2. Therefore, for this drug, particle size reduction was a 
suitable strategy to increase dissolution rate but it was less applicable for the development of a 
sustained release formulation. 
 
For the various formulations strategies tested F2 is the most suitable to obtain a long-acting 
pharmacokinetic (PK) profile which is illustrated by its higher average tmax,obs (3.0 h) 
compared to the other formulations. Additionally this formulation results in the highest 
plasma concentrations from three days after administration onwards until the end of the study 
(28 days). Consequently, compared to the other formulations tested, F2 released the highest 
amount of drug for the same amount of drug dosed, which was illustrated by its higher mean 
bioavailability value. This is definitely advantageous in terms of total mass of formulation to 
be suspended and therefore the volume to be administered. For (IM) injectable formulations 
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the volume injected is preferably as small as possible to avoid pain upon injection, irritation 
and inflammation. 
 
 
CONCLUSIONS 
In vivo evaluation of the different formulation strategies demonstrated the benefit of 
combining  water-soluble polymer PVP and a water-insoluble PLGA as a matrix for solid 
dispersions to develop long-term release formulations compared to the other formulation 
strategies assessed. The benefit is dual and comprises a more sustained release as well as a 
higher extent of drug release from the polymeric matrix. This was explained based on the 
structure of these PLGA/PVP-based matrices where the pore network originating from rapidly 
dissolving PVP results in an increasing access of the aqueous release medium to the API 
dispersed in the polymeric matrix. This increased access to drug dispersed in the matrix with 
depth from the surface acts as  a reservoir with a higher extent of and more prolonged drug 
release as a result. Moreover, the results suggest that for the PLGA/PVP-based formulations 
the release profile can be tailored by changing the molecular weight of PVP and the amount 
of PLGA in the matrix. 
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FIGURES 
Figure 1. Schematic representation of the polymeric formulations F1-F5 [11]. PLGA in green, 
PVP in red and API in yellow. 
 
 
Figure 2. Structural formula of the API, a poorly soluble HIV protease inhibitor. 
 
 
Figure 3. Plasma concentration-time profiles up to 28 days after IM administration of the six 
formulations F1-F6 (mean ± SD, n=4). 
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Figure 4. Plasma concentration-time profiles up to five hours after IM administration of the 
six formulations F1-F6 (mean ± SD, n=4).  
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Figure 5. Bioavailability 28 days after IM administration of the six formulations F1-F6 based 
on total plasma exposure of the API (AUC0-∞) (mean ± SD, n=4). 
 
 
Figure 6. Initial burst release 4 h post administration of the six formulations, expressed as the 
percentage of drug released (mean ± SD, n=4).  
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Figure 7. The structural evolution of a PLGA/PVP-based matrix and a PLGA-based matrix 
when exposed to a release environment, where A = short-term exposure and B = long-term 
exposure. PLGA in green, PVP in red and API in yellow. 
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Figure 8. SEM images. where A = F1 before exposure to a release medium, B = F1 before 
exposure to a release medium, C = F1 after exposure to a release medium, D = F4 after 
exposure to a release medium. F1 was selected as a representative for the PLGA/PVP-based 
formulations whereas F4 was chosen as an example for the PLGA-based formulations. 
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SUPPLEMENTARY INFORMATION 
Figure 1. Individual plasma concentration-time profiles up to 28 days after IM administration 
for the four test subjects (dog 1 - dog 4) of formulation F4. 
 
